Denali Therapeutics shares slumped for the second straight day Tuesday after the drugmaker's ALS treatment failed in a ...

Denali Therapeutics Inc. DNLI announced disappointing top-line results from an analysis of Regimen G of the phase II/III ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

To commemorate the 25th anniversary of Denali, GMC is offering customers a special 25th Anniversary Denali Package available ...

Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data ...

Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...

HAL is planning a $70 million expansion over the next three years, including the construction of a new guestroom building.

New research on the Denali Fault reveals three geologic sites were once united in a suture zone, marking the integration of ...

William Blair has initiated coverage on Denali Therapeutics Inc (NASDAQ:DNLI), a company focused on developing drugs for ...

The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.

Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks.

Mashpee Wampanoag educator Kitty Hendricks-Miller (Nanaweetah), consults on PBS 'Molly of Denali' as Cape-based tribe debuts ...